Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation

C Trento, ME Bernardo, A Nagler, S Kuçi, M Bornhäuser, U Köhl, D Strunk, A Galleu, F Sanchez-Guijo, Giuseppe Gaipa, M Introna, A Bukauskas, K Le Blanc, J Apperley, H Roelofs, A Van Campenhout, Y Beguin, J Kuball, L Lazzari, MA AvanziniW Fibbe, C Chabannon, C Bonini, Francesco Dazzi

Research output: Contribution to journalArticle

Abstract

The immunosuppressive properties of mesenchymal stromal cells (MSC) have been successfully tested to control clinical severe graft-versus host disease and improve survival. However, clinical studies have not yet provided conclusive evidence of their efficacy largely because of lack of patients’ stratification criteria. The heterogeneity of MSC preparations is also a major contributing factor, as manufacturing of therapeutic MSC is performed according to different protocols among different centers. Understanding the variability of the manufacturing protocol would allow a better comparison of the results obtained in the clinical setting among different centers. In order to acquire information on MSC manufacturing we sent a questionnaire to the European Society for Blood and Marrow Transplantation centers registered as producing MSC. Data from 17 centers were obtained and analyzed by means of a 2-phase questionnaire specifically focused on product manufacturing. Gathered information included MSC tissue sources, MSC donor matching, medium additives for ex vivo expansion, and data on MSC product specification for clinical release. The majority of centers manufactured MSC from bone marrow (88%), whilst only 2 centers produced MSC from umbilical cord blood or cord tissue. One of the major changes in the manufacturing process has been the replacement of fetal bovine serum with human platelet lysate as medium supplement. 59% of centers used only third-party MSC, whilst only 1 center manufactured exclusively autologous MSC. The large majority of these facilities (71%) administered MSC exclusively from frozen batches. Aside from variations in the culture method, we found large heterogeneity also regarding product specification, particularly in the markers used for phenotypical characterization and their threshold of expression, use of potency assays to test MSC functionality, and karyotyping. The initial data collected from this survey highlight the variability in MSC manufacturing as clinical products and the need for harmonization. Until more informative potency assays become available, a more homogeneous approach to cell production may at least reduce variability in clinical trials and improve interpretation of results. © 2018
Original languageEnglish
Pages (from-to)2365-2370
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume24
Issue number11
DOIs
Publication statusPublished - 2018

Fingerprint

Graft vs Host Disease
Mesenchymal Stromal Cells
Transplantation
Bone Marrow
Therapeutics
Surveys and Questionnaires
Karyotyping
Immunosuppressive Agents
Fetal Blood

Cite this

Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. / Trento, C; Bernardo, ME; Nagler, A; Kuçi, S; Bornhäuser, M; Köhl, U; Strunk, D; Galleu, A; Sanchez-Guijo, F; Gaipa, Giuseppe; Introna, M; Bukauskas, A; Le Blanc, K; Apperley, J; Roelofs, H; Van Campenhout, A; Beguin, Y; Kuball, J; Lazzari, L; Avanzini, MA; Fibbe, W; Chabannon, C; Bonini, C; Dazzi, Francesco.

In: Biology of Blood and Marrow Transplantation, Vol. 24, No. 11, 2018, p. 2365-2370.

Research output: Contribution to journalArticle

Trento, C, Bernardo, ME, Nagler, A, Kuçi, S, Bornhäuser, M, Köhl, U, Strunk, D, Galleu, A, Sanchez-Guijo, F, Gaipa, G, Introna, M, Bukauskas, A, Le Blanc, K, Apperley, J, Roelofs, H, Van Campenhout, A, Beguin, Y, Kuball, J, Lazzari, L, Avanzini, MA, Fibbe, W, Chabannon, C, Bonini, C & Dazzi, F 2018, 'Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation', Biology of Blood and Marrow Transplantation, vol. 24, no. 11, pp. 2365-2370. https://doi.org/10.1016/j.bbmt.2018.07.015
Trento, C ; Bernardo, ME ; Nagler, A ; Kuçi, S ; Bornhäuser, M ; Köhl, U ; Strunk, D ; Galleu, A ; Sanchez-Guijo, F ; Gaipa, Giuseppe ; Introna, M ; Bukauskas, A ; Le Blanc, K ; Apperley, J ; Roelofs, H ; Van Campenhout, A ; Beguin, Y ; Kuball, J ; Lazzari, L ; Avanzini, MA ; Fibbe, W ; Chabannon, C ; Bonini, C ; Dazzi, Francesco. / Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. In: Biology of Blood and Marrow Transplantation. 2018 ; Vol. 24, No. 11. pp. 2365-2370.
@article{c9f9e834364e445dbe2b8c61ab79073f,
title = "Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation",
abstract = "The immunosuppressive properties of mesenchymal stromal cells (MSC) have been successfully tested to control clinical severe graft-versus host disease and improve survival. However, clinical studies have not yet provided conclusive evidence of their efficacy largely because of lack of patients’ stratification criteria. The heterogeneity of MSC preparations is also a major contributing factor, as manufacturing of therapeutic MSC is performed according to different protocols among different centers. Understanding the variability of the manufacturing protocol would allow a better comparison of the results obtained in the clinical setting among different centers. In order to acquire information on MSC manufacturing we sent a questionnaire to the European Society for Blood and Marrow Transplantation centers registered as producing MSC. Data from 17 centers were obtained and analyzed by means of a 2-phase questionnaire specifically focused on product manufacturing. Gathered information included MSC tissue sources, MSC donor matching, medium additives for ex vivo expansion, and data on MSC product specification for clinical release. The majority of centers manufactured MSC from bone marrow (88{\%}), whilst only 2 centers produced MSC from umbilical cord blood or cord tissue. One of the major changes in the manufacturing process has been the replacement of fetal bovine serum with human platelet lysate as medium supplement. 59{\%} of centers used only third-party MSC, whilst only 1 center manufactured exclusively autologous MSC. The large majority of these facilities (71{\%}) administered MSC exclusively from frozen batches. Aside from variations in the culture method, we found large heterogeneity also regarding product specification, particularly in the markers used for phenotypical characterization and their threshold of expression, use of potency assays to test MSC functionality, and karyotyping. The initial data collected from this survey highlight the variability in MSC manufacturing as clinical products and the need for harmonization. Until more informative potency assays become available, a more homogeneous approach to cell production may at least reduce variability in clinical trials and improve interpretation of results. {\circledC} 2018",
author = "C Trento and ME Bernardo and A Nagler and S Ku{\cc}i and M Bornh{\"a}user and U K{\"o}hl and D Strunk and A Galleu and F Sanchez-Guijo and Giuseppe Gaipa and M Introna and A Bukauskas and {Le Blanc}, K and J Apperley and H Roelofs and {Van Campenhout}, A and Y Beguin and J Kuball and L Lazzari and MA Avanzini and W Fibbe and C Chabannon and C Bonini and Francesco Dazzi",
year = "2018",
doi = "10.1016/j.bbmt.2018.07.015",
language = "English",
volume = "24",
pages = "2365--2370",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation

AU - Trento, C

AU - Bernardo, ME

AU - Nagler, A

AU - Kuçi, S

AU - Bornhäuser, M

AU - Köhl, U

AU - Strunk, D

AU - Galleu, A

AU - Sanchez-Guijo, F

AU - Gaipa, Giuseppe

AU - Introna, M

AU - Bukauskas, A

AU - Le Blanc, K

AU - Apperley, J

AU - Roelofs, H

AU - Van Campenhout, A

AU - Beguin, Y

AU - Kuball, J

AU - Lazzari, L

AU - Avanzini, MA

AU - Fibbe, W

AU - Chabannon, C

AU - Bonini, C

AU - Dazzi, Francesco

PY - 2018

Y1 - 2018

N2 - The immunosuppressive properties of mesenchymal stromal cells (MSC) have been successfully tested to control clinical severe graft-versus host disease and improve survival. However, clinical studies have not yet provided conclusive evidence of their efficacy largely because of lack of patients’ stratification criteria. The heterogeneity of MSC preparations is also a major contributing factor, as manufacturing of therapeutic MSC is performed according to different protocols among different centers. Understanding the variability of the manufacturing protocol would allow a better comparison of the results obtained in the clinical setting among different centers. In order to acquire information on MSC manufacturing we sent a questionnaire to the European Society for Blood and Marrow Transplantation centers registered as producing MSC. Data from 17 centers were obtained and analyzed by means of a 2-phase questionnaire specifically focused on product manufacturing. Gathered information included MSC tissue sources, MSC donor matching, medium additives for ex vivo expansion, and data on MSC product specification for clinical release. The majority of centers manufactured MSC from bone marrow (88%), whilst only 2 centers produced MSC from umbilical cord blood or cord tissue. One of the major changes in the manufacturing process has been the replacement of fetal bovine serum with human platelet lysate as medium supplement. 59% of centers used only third-party MSC, whilst only 1 center manufactured exclusively autologous MSC. The large majority of these facilities (71%) administered MSC exclusively from frozen batches. Aside from variations in the culture method, we found large heterogeneity also regarding product specification, particularly in the markers used for phenotypical characterization and their threshold of expression, use of potency assays to test MSC functionality, and karyotyping. The initial data collected from this survey highlight the variability in MSC manufacturing as clinical products and the need for harmonization. Until more informative potency assays become available, a more homogeneous approach to cell production may at least reduce variability in clinical trials and improve interpretation of results. © 2018

AB - The immunosuppressive properties of mesenchymal stromal cells (MSC) have been successfully tested to control clinical severe graft-versus host disease and improve survival. However, clinical studies have not yet provided conclusive evidence of their efficacy largely because of lack of patients’ stratification criteria. The heterogeneity of MSC preparations is also a major contributing factor, as manufacturing of therapeutic MSC is performed according to different protocols among different centers. Understanding the variability of the manufacturing protocol would allow a better comparison of the results obtained in the clinical setting among different centers. In order to acquire information on MSC manufacturing we sent a questionnaire to the European Society for Blood and Marrow Transplantation centers registered as producing MSC. Data from 17 centers were obtained and analyzed by means of a 2-phase questionnaire specifically focused on product manufacturing. Gathered information included MSC tissue sources, MSC donor matching, medium additives for ex vivo expansion, and data on MSC product specification for clinical release. The majority of centers manufactured MSC from bone marrow (88%), whilst only 2 centers produced MSC from umbilical cord blood or cord tissue. One of the major changes in the manufacturing process has been the replacement of fetal bovine serum with human platelet lysate as medium supplement. 59% of centers used only third-party MSC, whilst only 1 center manufactured exclusively autologous MSC. The large majority of these facilities (71%) administered MSC exclusively from frozen batches. Aside from variations in the culture method, we found large heterogeneity also regarding product specification, particularly in the markers used for phenotypical characterization and their threshold of expression, use of potency assays to test MSC functionality, and karyotyping. The initial data collected from this survey highlight the variability in MSC manufacturing as clinical products and the need for harmonization. Until more informative potency assays become available, a more homogeneous approach to cell production may at least reduce variability in clinical trials and improve interpretation of results. © 2018

U2 - 10.1016/j.bbmt.2018.07.015

DO - 10.1016/j.bbmt.2018.07.015

M3 - Article

VL - 24

SP - 2365

EP - 2370

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 11

ER -